期刊文献+

托法替尼治疗类风湿关节炎有效性和安全性研究进展 被引量:10

原文传递
导出
摘要 RA因对关节及周围组织造成不可逆的破坏,过去被称为“不死的癌症”。随着生物制剂等抗风湿药物的快速发展,多数RA的患者可获得快速、有效的临床缓解。近年来,随着对RA发病机制研究的不断深入,针对Janus激酶(JAK)-转录激活因子(STAT)、Wnt和NF-κB等信号通路的新药研发进展也非常快。
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2015年第7期490-492,I0002,共4页 Chinese Journal of Rheumatology
基金 基金项目:国家自然科学基金(81471607,81273284) 上海市科委基础研究重点课题(12DZ1931003)
  • 相关文献

参考文献19

  • 1Lee EB,Fleischmann R,Hall S,et al.Tofacitinib versus methotrexate in rheumatoid arthritis[J].New Engl J Med,2014,370(25):2377-2386.
  • 2Bannwarth B,Kostine M,Poursac N.A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis[J].Expert Opin Drug Metab Toxicol,2013,9(6):753-761.
  • 3Fleischmann R,Cutolo M,Genovese MC,et al.Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib(CP-690,550)or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs[J].Arthritis Rheum,2012,64(3):617-629.
  • 4Kremer JM,Cohen S,Wilkinson BE,et al.A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib(CP-690,550)versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone[J].Arthritis Rheum,2012,64(4):970-981.
  • 5Fleischmann R,Kremer J,Cush J,et al.Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J].N Engl J Med,2012,367(6):495-507.
  • 6Burmester GR,Blanco R,Charles-Schoeman C,et al.Tofaci tinib(CP-690,550)in combination with methotrexate in patientswith active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors:a randomised phase 3 trial[J].Lancet,2013,381(9865):451-460.
  • 7Van Vollenhoven RF,Fleischmann R,Cohen S,et al.Tofacitinib or adalimumab versus placebo in rheumatoid arthritis[J].NEW Engl J Med,2012,367(6):508-519.
  • 8Kremer J,Li ZG,Hall S,et al.Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis:a randomized trial[J].Ann Intern Med,2013,159(4):253-261.
  • 9Van der Heijde D,Tarvaka Y,Fleischmann R,et al.Tofacitinib(CP-690,550)in patients with rheumatoid arthritis receiving methotrexate:twelve-month data from a twenty-four-month phase M randomized radiographic study[J].Arthritis Rheum,2013,65(3):559-570.
  • 10Krishnaswami S,Kudlacz E,Wang R,et al.A supratherapeutic dose of the Janus kinase inhibitor tasocitinib(CP-690,550)does not prolong QTc interval in healthy participants[J].J Clin Pharmacol,2011,51(9):1256-1263.

同被引文献68

引证文献10

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部